We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents in late-stage development for asthma and rhinosinusitis with nasal polyps, Stargardt disease, and wet age-related macular degeneration (wet AMD).
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- An update on the human immunodeficiency virus (HIV)-1 pre-exposure prophylaxis (PrEP) market.
- An overview of the pipeline for selective estrogen receptor degraders (SERDs) in breast cancer.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
You may also be interested in:
Q3 2025 CarelonRx DrugInsights Update
Regulatory and Legislative Activity Update Q3 2025
